104 related articles for article (PubMed ID: 8092109)
1. A phase II trial of recombinant leukocyte interferon plus doxorubicin in patients with hepatocellular carcinoma.
Feun LG; Savaraj N; Hung S; Reddy R; Jeffers L; Benedetto P; Livingstone AS; Ardalan B; Levi JU; Parker T
Am J Clin Oncol; 1994 Oct; 17(5):393-5. PubMed ID: 8092109
[TBL] [Abstract][Full Text] [Related]
2. Recombinant leukocyte interferon, doxorubicin, and 5FUDR in patients with hepatocellular carcinoma-A phase II trial.
Feun LG; O'Brien C; Molina E; Rodriguez M; Jeffers L; Schiff ER; Marini A; Savaraj N; Ardalan B
J Cancer Res Clin Oncol; 2003 Jan; 129(1):17-20. PubMed ID: 12618896
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of recombinant leukocyte A interferon (IFN-alpha 2A, Roferon-A) with doxorubicin in advanced malignant disease.
Creagan ET; Frytak S; Long HJ; Kvols LK
Cancer; 1989 Sep; 64(5):1034-7. PubMed ID: 2474365
[TBL] [Abstract][Full Text] [Related]
4. Combined doxorubicin and alpha-interferon therapy of advanced hepatocellular carcinoma.
Kardinal CG; Moertel CG; Wieand HS; Schutt AJ; O'Connell MJ; Wright K; Wiesenfeld M; Tschetter LK; Krook JE
Cancer; 1993 Apr; 71(7):2187-90. PubMed ID: 8384064
[TBL] [Abstract][Full Text] [Related]
5. Recombinant leukocyte A interferon with doxorubicin. A phase I study in advanced solid neoplasms and implications for hepatocellular carcinoma.
Creagan ET; Long HJ; Frytak S; Moertel CG
Cancer; 1988 Jan; 61(1):19-22. PubMed ID: 2825959
[TBL] [Abstract][Full Text] [Related]
6. A phase I trial of interferon-alpha-2a plus cyclophosphamide, vincristine, prednisone, and doxorubicin.
Schiller JH; Hawkins MJ; O'Connell MJ; Sielaff K; Borden EC
J Biol Response Mod; 1989 Jun; 8(3):252-61. PubMed ID: 2746297
[TBL] [Abstract][Full Text] [Related]
7. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma.
Yeo W; Mok TS; Zee B; Leung TW; Lai PB; Lau WY; Koh J; Mo FK; Yu SC; Chan AT; Hui P; Ma B; Lam KC; Ho WM; Wong HT; Tang A; Johnson PJ
J Natl Cancer Inst; 2005 Oct; 97(20):1532-8. PubMed ID: 16234567
[TBL] [Abstract][Full Text] [Related]
8. Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy.
Leung TW; Tang AM; Zee B; Yu SC; Lai PB; Lau WY; Johnson PJ
Cancer; 2002 Jan; 94(2):421-7. PubMed ID: 11905412
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of combination doxorubicin, interferon-alpha, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma.
Lu YS; Hsu C; Li CC; Kuo SH; Yeh KH; Yang CH; Hsu CH; Wu CY; Cheng AL
Hepatogastroenterology; 2004; 51(57):815-9. PubMed ID: 15143923
[TBL] [Abstract][Full Text] [Related]
10. Biochemical modulation of doxorubicin by high-dose tamoxifen in the treatment of advanced hepatocellular carcinoma.
Cheng AL; Yeh KH; Fine RL; Chuang SE; Yang CH; Wang LH; Chen DS
Hepatogastroenterology; 1998; 45(24):1955-60. PubMed ID: 9951847
[TBL] [Abstract][Full Text] [Related]
11. A phase I study of recombinant human interleukin-2 and alpha-interferon-2a in patients with renal cell cancer, colorectal cancer, and malignant melanoma.
Mittelman A; Huberman M; Puccio C; Fallon B; Tessitore J; Savona S; Eyre R; Gafney E; Wick M; Skelos A
Cancer; 1990 Aug; 66(4):664-9. PubMed ID: 2386896
[TBL] [Abstract][Full Text] [Related]
12. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma.
Leung TW; Patt YZ; Lau WY; Ho SK; Yu SC; Chan AT; Mok TS; Yeo W; Liew CT; Leung NW; Tang AM; Johnson PJ
Clin Cancer Res; 1999 Jul; 5(7):1676-81. PubMed ID: 10430068
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of alpha 2-interferon plus doxorubicin in patients with solid tumors.
Sarosy GA; Brown TD; Von Hoff DD; Spiegel RJ; Golando JP; Beougher KL; Kuhn JG; Kisner DL
Cancer Res; 1986 Oct; 46(10):5368-71. PubMed ID: 3756887
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma.
Lee J; Park JO; Kim WS; Park SH; Park KW; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC; Joh J; Kim K; Jung CW; Park YS; Im YH; Kang WK; Lee MH; Park K
Cancer Chemother Pharmacol; 2004 Nov; 54(5):385-90. PubMed ID: 15248028
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of high-dose bolus interleukin-2 and interferon alfa-2a in patients with metastatic malignancy.
Budd GT; Murthy S; Finke J; Sergi J; Gibson V; Medendorp S; Barna B; Boyett J; Bukowski RM
J Clin Oncol; 1992 May; 10(5):804-9. PubMed ID: 1569452
[TBL] [Abstract][Full Text] [Related]
16. Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy.
Akçali Z; Akin E; Ozyilkan O
Cancer; 2002 Nov; 95(9):2038-9; author reply 2039. PubMed ID: 12404300
[No Abstract] [Full Text] [Related]
17. Phase 1-2 trial of PTK787/ZK222584 combined with intravenous doxorubicin for treatment of patients with advanced hepatocellular carcinoma: implication for antiangiogenic approach to hepatocellular carcinoma.
Yau T; Chan P; Pang R; Ng K; Fan ST; Poon RT
Cancer; 2010 Nov; 116(21):5022-9. PubMed ID: 20629034
[TBL] [Abstract][Full Text] [Related]
18. A phase II evaluation of clofazimine plus doxorubicin in advanced, unresectable primary hepatocellular carcinoma.
Falkson CI; Falkson G
Oncology; 1999 Oct; 57(3):232-5. PubMed ID: 10545792
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study.
Dutcher JP; Logan T; Gordon M; Sosman J; Weiss G; Margolin K; Plasse T; Mier J; Lotze M; Clark J; Atkins M
Clin Cancer Res; 2000 Sep; 6(9):3442-50. PubMed ID: 10999727
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma.
Patt YZ; Hassan MM; Lozano RD; Brown TD; Vauthey JN; Curley SA; Ellis LM
J Clin Oncol; 2003 Feb; 21(3):421-7. PubMed ID: 12560429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
